Document is current
Any future updates will be listed below
-
Authors
Cohen-Sharir, Yael
McFarland, James M. https://orcid.org/0000-0001-9978-480X
Abdusamad, Mai
Marquis, Carolyn
Bernhard, Sara V.
Kazachkova, Mariya
Tang, Helen
Ippolito, Marica R.
Laue, Kathrin
Zerbib, Johanna
Malaby, Heidi L. H.
Jones, Andrew
Stautmeister, Lisa-Marie
Bockaj, Irena
Wardenaar, René
Lyons, Nicholas
Nagaraja, Ankur https://orcid.org/0000-0002-8586-3117
Bass, Adam J. https://orcid.org/0000-0002-8193-4758
Spierings, Diana C. J. https://orcid.org/0000-0001-8403-474X
Foijer, Floris https://orcid.org/0000-0003-0989-3127
Beroukhim, Rameen https://orcid.org/0000-0001-6303-3609
Santaguida, Stefano https://orcid.org/0000-0002-1501-6190
Golub, Todd R. https://orcid.org/0000-0003-0113-2403
Stumpff, Jason
Storchová, Zuzana https://orcid.org/0000-0003-2376-7047
Ben-David, Uri https://orcid.org/0000-0001-7098-2378
- License Information
-
More Information
Article History
Received: 4 March 2020
Accepted: 19 November 2020
First Online: 27 January 2021
Competing interests
: T.R.G. is a consultant to GlaxoSmithKline and is a founder of Sherlock Biosciences. R.B. owns shares in Ampressa and receives grant funding from Novartis. A.J.B. receives funding from Merck, Bayer and Novartis, and is an advisor to Earli and Helix Nano and a co-founder of Signet Therapeutics. The other authors declare no competing interests.
